# CORRECTION

## **Open Access**



Correction: A multicenter, double-blind, randomized, parallel-group, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study)

Taku Kinoshita<sup>1,2</sup>, Masahiro Shinoda<sup>3</sup>, Yasuhiro Nishizaki<sup>4</sup>, Katsuya Shiraki<sup>5</sup>, Yuji Hirai<sup>6</sup>, Yoshiko Kichikawa<sup>7</sup>, Kenji Tsushima<sup>1</sup>, Masaharu Shinkai<sup>3</sup>, Naoyuki Komura<sup>8</sup>, Kazuo Yoshida<sup>9</sup>, Yasutoshi Kido<sup>10,11,12</sup>, Hiroshi Kakeya<sup>13,14</sup>, Naoto Uemura<sup>15\*</sup> and Junichi Kadota<sup>16,17</sup>

### Correction: BMC Med 20, 342 (2022) https://doi.org/10.1186/s12916-022-02518-7

The original article [1] contained a small typo in Masaharu Shinkai's name which has since been corrected.

#### Author details

<sup>1</sup>Department of Pulmonary Medicine, International University of Health and Welfare Narita Hospital, Narita, Japan. <sup>2</sup>Present Address: Respiratory Medicine, Chiba Rosai Hospital, Chiba, Japan. <sup>3</sup>Department of Respiratory Medicine, Tokyo Shinagawa Hospital, Tokyo, Japan. <sup>4</sup>Tokai University Tokyo Hospital, Tokyo, Japan. <sup>5</sup>Department of General and Laboratory Medicine, Mie Prefectural General Medical Center, Yokkaichi, Japan. <sup>6</sup>Department of Infectious Diseases, Tokyo Medical University Hachioji Medical Center, Hachioji, Japan. <sup>7</sup>Department of Respiratory Medicine, Mishuku Hospital, Tokyo, Japan. <sup>8</sup>Clinical Development Planning, Ono Pharmaceutical Co., Ltd., Osaka, Japan. <sup>9</sup>Department of Statistical Analysis, Ono Pharmaceutical Co., Ltd., Osaka, Japan. <sup>10</sup>Department of Parasitology and Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka City University, Osaka, Japan. <sup>11</sup>Department of Virology and Parasitology, Graduate School of Medicine,

The original article can be found online at https://doi.org/10.1186/s12916-022-02518-7.

\*Correspondence: uemura@oita-u.ac.jp

<sup>15</sup> Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita-ken 879-5593, Japan

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/flicenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Osaka Metropolitan University, Osaka, Japan.<sup>12</sup>Research Center for Infectious Disease Sciences, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.<sup>13</sup>Department of Infection Control Science, Graduate School of Medicine, Osaka City University, Osaka, Japan.<sup>14</sup>Department of Infection Control Science, Graduate School of Medicine, Osaka Metropolitan University, Osaka, Japan.<sup>15</sup>Department of Clinical Pharmacology and Therapeutics, Faculty of Medicine, Oita University, 1-1 Idaigaoka, Hasama-machi, Yufu-shi, Oita-ken 879-5593, Japan.<sup>16</sup>Department of Respiratory Medicine and Infectious Diseases, Faculty of Medicine, Oita University, Oita, Japan.<sup>17</sup>Nagasaki Harbor Medical Center, Nagasaki, Japan.

#### Published online: 08 December 2022

#### Reference

 Kinoshita T, et al. A multicenter, double-blind, randomized, parallelgroup, placebo-controlled study to evaluate the efficacy and safety of camostat mesilate in patients with COVID-19 (CANDLE study). BMC Med. 2022;20:342. https://doi.org/10.1186/s12916-022-02518-7.